<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04996056</url>
  </required_header>
  <id_info>
    <org_study_id>TNX-CE-CI201</org_study_id>
    <nct_id>NCT04996056</nct_id>
  </id_info>
  <brief_title>An Open-Label, Randomized Pilot Study Comparing the Safety of a Single Dose of TNX-1300 to Usual Care (UC) Alone for the Treatment of Signs and Symptoms of Acute Cocaine Intoxication in Male Emergency Department (ED) Subjects</brief_title>
  <official_title>An Open-Label, Randomized Pilot Study Comparing the Safety of a Single Dose of TNX-1300 to Usual Care (UC) Alone for the Treatment of Signs and Symptoms of Acute Cocaine Intoxication in Male Emergency Department (ED) Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tonix Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tonix Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open-Label, Randomized Pilot Study Comparing the Safety of a Single Dose of TNX-1300 to&#xD;
      Usual Care (UC) Alone for the Treatment of Signs and Symptoms of Acute Cocaine Intoxication&#xD;
      in Male Emergency Department (ED) Subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events, Adverse Events of Special Interests, and Adverse Drug Reactions</measure>
    <time_frame>Baseline to 12 Hours</time_frame>
    <description>Incidence of Treatment Emergent Adverse Events, Adverse Events of Special Interests, and Adverse Drug Reactions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of cardiovascular and other signs and symptoms associated with acute cocaine intoxication identified at Baseline on the Stimulant Intoxication Scale (SIS)</measure>
    <time_frame>Baseline to 6 Hours</time_frame>
    <description>Reduction of cardiovascular and other signs and symptoms associated with acute cocaine intoxication identified at Baseline on the Stimulant Intoxication Scale (SIS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of circulating cocaine, cocaethylene, and EME levels after 15, 60, 120, 240, and 360 minutes in the TNX-1300 arm compared to Baseline</measure>
    <time_frame>Baseline to 6 Hours</time_frame>
    <description>Reduction of circulating cocaine, cocaethylene, and EME levels after 15, 60, 120, 240, and 360 minutes in the TNX-1300 arm compared to Baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Cocaine Intoxication</condition>
  <arm_group>
    <arm_group_label>TNX-1300</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TNX-1300 Intravenous injection 200 mg once over 2 mins</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Usual Care per the Emergency Department protocol for treating Cocaine Intoxication</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TNX-1300</intervention_name>
    <description>TNX 1300 200 mg Intravenous injection</description>
    <arm_group_label>TNX-1300</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>Usual Care per the Emergency Department protocol for Cocaine Intoxication</description>
    <arm_group_label>Usual Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is male (sex assigned at birth).&#xD;
&#xD;
          2. Subject is 18-50 years of age.&#xD;
&#xD;
          3. Subject has the capacity to provide voluntary written informed consent.&#xD;
&#xD;
          4. At Screening, subject presents with a SIS total score of â‰¥6 and a score &gt;1 on at least&#xD;
             1 of the 3 cardiovascular items (HR, systolic and diastolic BP).&#xD;
&#xD;
          5. At Screening, subject presents with cardiac symptoms not present prior to cocaine&#xD;
             intoxication, with or without behavioral symptoms.&#xD;
&#xD;
          6. Subject has a positive urine drug screen test at Screening to confirm cocaine use and&#xD;
             detect polysubstance abuse (subject may test positive for cannabinoids or opiates).&#xD;
&#xD;
          7. Subject is a suitable candidate for investigational treatment based on the opinion of&#xD;
             the investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject who has been admitted to the ED involuntarily.&#xD;
&#xD;
          2. Subject who participated in this clinical study previously.&#xD;
&#xD;
          3. Subject received naloxone (Narcan) within 3 hours prior to informed consent.&#xD;
&#xD;
          4. Subject tests positive for 3,4-Methylenedioxymethamphetamine (MDMA) or amphetamine at&#xD;
             Screening.&#xD;
&#xD;
          5. Subject has a prior or current clinically significant untreated cardiac condition.&#xD;
             Untreated hypertension may be allowed if not considered severe or life threatening.&#xD;
&#xD;
          6. Subject incurred or is likely to incur a myocardial infarction or other&#xD;
             life-threatening severe event or has acute ECG changes indicative of acute coronary&#xD;
             syndrome according to investigator judgment.&#xD;
&#xD;
          7. Subject has a clinically significant or unstable medical illness, condition, or&#xD;
             disorder that would be anticipated to potentially compromise subject safety or&#xD;
             adversely affect the evaluation of clinical outcome parameters.&#xD;
&#xD;
          8. Subject requires physical restraints due to physiological and/or behavioral symptoms.&#xD;
&#xD;
          9. Participation in another investigational drug study (current or within 30 days of&#xD;
             Screening).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 3, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Poisoning</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

